Download PDF
Thromb Haemost 1998; 80(06): 1029-1030
DOI: 10.1055/s-0037-1615408
Letters to the Editor
Schattauer GmbH

The 4G/5G Polymorphism of PAI-1 Promoter Gene and the Risk of Myocardial Infarction: A Meta-analysis

Licia Iacoviello
1   Istituto di Ricerche Farmacologiche Mario Negri, Unit of Genetics of Vascular Risk Factors, “Angela Valenti” Laboratory of Thrombosis Pharmacology, Department of Vascular Medicine and Pharmacology
3   Gaubius Laboratory, TNO-PG, Leiden, The Netherlands
,
Francesco Burzotta   *
1   Istituto di Ricerche Farmacologiche Mario Negri, Unit of Genetics of Vascular Risk Factors, “Angela Valenti” Laboratory of Thrombosis Pharmacology, Department of Vascular Medicine and Pharmacology
,
Augusto Di Castelnuovo
1   Istituto di Ricerche Farmacologiche Mario Negri, Unit of Genetics of Vascular Risk Factors, “Angela Valenti” Laboratory of Thrombosis Pharmacology, Department of Vascular Medicine and Pharmacology
,
Francesco Zito   **
1   Istituto di Ricerche Farmacologiche Mario Negri, Unit of Genetics of Vascular Risk Factors, “Angela Valenti” Laboratory of Thrombosis Pharmacology, Department of Vascular Medicine and Pharmacology
,
Roberto Marchioli
2   Laboratory of Clinical Epidemiology of Cardiovascular Disease, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
,
Maria Benedetta Donati
1   Istituto di Ricerche Farmacologiche Mario Negri, Unit of Genetics of Vascular Risk Factors, “Angela Valenti” Laboratory of Thrombosis Pharmacology, Department of Vascular Medicine and Pharmacology
› Author Affiliations
Further Information

Publication History

Received 30 March 1998

Accepted after resubmission 12 August 1998

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

 

* On leave of absence from the Institute of Cardiology, Catholic University, Rome, Italy


** Recipient of a Mario Negri Institute Fellowship “ALUMNI Association”


 

  • References

  • 1 Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.. Proc Natl Acad Sci USA 1995; 92: 1851-55.
    CrossrefPubMedGoogle Scholar
  • 2 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to inter-leukin 1 in HepG2 cells.. J Biol Chem 1993; 268: 10739-45.
    PubMedGoogle Scholar
  • 3 Ye S, Greeen FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor 1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study.. Thromb Haemost 1995; 74: 837-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes.. Thromb Haemost 1995; 74: 1032-34.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.. Arterioscler Thromb Vasc Biol 1998; 17: 33-7.
    PubMedGoogle Scholar
  • 6 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.. Circulation 1998; 95: 59-62.
    PubMedGoogle Scholar
  • 7 Burzotta F, Di Castelnuovo A, Amore C, D’Orazio A, Donati MB, Iacoviello L. 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction: a case-control study in a sample of GISSI-2 patients.. Thromb Haemost 1998; 78: 1294-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Colaizzo D, Margaglione M, Lirato C, Grandone E, Cappucci G, Fischetti A, Mancini FP, Pauciullo P, Di Minno G. Plasminogen activator inhibitor 1 4G/5G in subjects with a history of juvenile coronary heart disease.. Thromb Haemost 1998; Suppl: 97 (Abstract).
    PubMedGoogle Scholar
  • 9 van der Bom JC, Bots ML, Slagboom PE, Haverkate F, Meijer P, Kluft C, Grobbee DE. The risk of smoking is modified by the 4G allele of the PAI-1 gene.. Thromb Haemost 1998; Suppl: 579 (Abstract).
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Petitti DB. Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis.. Oxford University Press 1994.
    PubMedGoogle Scholar
  • 11 Marchioli R, Marfisi RM, Carinci F, Tognoni G. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary artery disease.. Arch Intern Med 1996; 156: 1158-72.
    CrossrefPubMedGoogle Scholar